Rituximab Biosimilar Market Size, Share & Trends Analysis Report By Brand, By Application, By Route of Administration, By Molecule Type, By Distribution Channel Region And Segment Forecasts, 2025-2034

Report Id: 1081 Pages: 180 Last Updated: 16 June 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Rituximab Biosimilar Market Segmentation

Global Rituximab Biosimilar Market Outlook By Brand

  • Riabni
  • Rituxan
  • Rituxan Hycela
  • Ruxience
  • Truxima
  • Riximyo
  • Truxima
  • Rixathon
  • Blitzima
  • Ruxience
  • Ituxredi
  • Others (Products approved in developing countries & pipeline products)

 rituximab

Global Rituximab Biosimilar Market Outlook By Application

  • Non-Hodgkin’s Lymphoma
  • Chronic Lymhocytic Leukemia
  • Rheumatoid Arthritis and other disease
  • Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

 

Global Rituximab Biosimilar Market Outlook By Route of Administration

  • Subcutaneous
  • Intravenous
  • Parenteral
  • Molecule Type

Global Rituximab Biosimilar Market Outlook By Molecule Type

  • Monoclonal antibodies
  • Peptide
  • Protein
  • Small molecule
  • Product Type

Global Rituximab Biosimilar Market Outlook By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other 

Global Rituximab Biosimilar Market Outlook By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary
Chapter 3. Global Rituximab Biosimilar Market Snapshot
Chapter 4. Global Rituximab Biosimilar Market Variables, Trends & Scope

4.1. Market Segmentation & Scope
4.2. Market Dynamics - Drivers
4.3. Challenges/Restraints
4.4. Market Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Clinical Trials/Pipeline Analysis -2019
4.7. Historic Revenue of Originator Drug: MabThera / Rituxan (rituximab)
4.8. COVID 19 Impact on Pharmaceutical Industry

Chapter 5. Market Segmentation 1: Application Estimates & Trend Analysis

5.1. Application & Market Share, 2024 & 2034
5.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Application:

5.2.1. Riabni
5.2.2. Rituxan
5.2.3. Rituxan Hycela
5.2.4. Ruxience
5.2.5. Truxima
5.2.6. Riximyo
5.2.7. Truxima
5.2.8. Rixathon
5.2.9. Blitzima
5.2.10. Ruxience
5.2.11. Ituxredi
5.2.12. Others (Products approved in developing countries & pipeline products)

Chapter 6. Market Segmentation 2: Route Of Administration Estimates & Trend Analysis

6.1. Application & Market Share, 2024 & 2034
6.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:

6.2.1. Subcutaneous
6.2.2. Intravenous
6.2.3. Parenteral
6.2.4. Molecule Type

Chapter 7. Market Segmentation 3: Molecule Type Estimates & Trend Analysis
7.1. Application & Market Share, 2024 & 2034
7.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule Type:

7.2.1. Monoclonal antibodies
7.2.2. Peptide
7.2.3. Protein
7.2.4. Small molecule
7.2.5. Product Type

Chapter 8. Rituximab Biosimilar Market Segmentation 4: Distribution Channels Estimates & Trend Analysis
8.1. Distribution Channels Analysis & Market Share, 2024 & 2034
8.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channels:

8.2.1. Hospital Pharmacy
8.2.2. Online Pharmacy
8.2.3. Retail Pharmacy
8.2.4. Other Direct Distribution Channels

Chapter 9. Rituximab Biosimilar Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America
9.1.1. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.1.2. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.1.3. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.1.4. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.1.5. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2021-2034

9.1.5.1. U.S.
9.1.5.2. Canada

9.2. Europe
9.2.1. Europe Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.2.2. Europe Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.2.3. Europe Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.2.4. Europe Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.2.5. Europe Rituximab Biosimilar Market revenue (US$ Million) by country, 2021-2034

9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe

9.3. Asia Pacific
9.3.1. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.3.2. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.3.3. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.3.4. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.3.5. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) by country, 2021-2034

9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific

9.4. Latin America
9.4.1. Latin America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.4.2. Latin America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.4.3. Latin America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.4.4. Latin America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.4.5. Latin America Rituximab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2021-2034

9.4.5.1. Brazil
9.4.5.2. Rest of Latin America

9.5. MEA
9.5.1. MEA Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.5.2. MEA Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.5.3. MEA Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.5.4. MEA Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.5.5. MEA revenue Rituximab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2021-2034

9.5.5.1. South Africa
9.5.5.2. Rest of MEA

Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances in Biosimilar Industry
10.2. Company Profiles

10.2.1. Amgen Inc.

10.2.1.1. Company Overview
10.2.1.2. Financials
10.2.1.3. Rituximab Product Portfolio - ABP 798
10.2.1.4. Business Strategy & Recent Developments

10.2.2. GENENTECH
10.2.3. Pfizer Inc.
10.2.4. Celltrion, Inc.
10.2.5. Sandoz GmbH
10.2.6. Sandoz GmbH
10.2.7. Dr. Reddy’s Laboratories
10.2.8. Biocad
10.2.9. Shanghai Henlius Biotech
10.2.10. AryoGen Pharmed
10.2.11. Laboratorios PiSA
10.2.12. Other prominent players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
2539
Security Code field cannot be blank!

Frequently Asked Questions

The Rituximab Biosimilar Market is expected to grow at a 12.3% CAGR during the forecast period for 2025-2034.

Amgen Inc., Pfizer Inc., Sandoz International GmbH, Celltrion Healthcare Co., Ltd., Mylan Inc., Reliance Life Sciences, Teva Pharmaceutical Industries

Brand, Application, Route of Administration, Molecule Type and Distribution Channel are the key segments of the Rituximab Biosimilar Market.

Europe region is leading the Rituximab Biosimilar Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying